# EDGAR Filing Document

**Accession Number:** 0001557746
**File Stem:** 0001209191-23-002351
**Filing Date:** 2023-1
**Character Count:** 11421
**Document Hash:** 4e3aa7dbf466af44dbfb670f19e82b91
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-002351.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001209191-23-002351

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Balthaser Kevin
- **CENTRAL INDEX KEY:** 0001957554

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37581
- **FILM NUMBER:** 23515481

**MAIL ADDRESS:**
- **STREET 1:** C/O ACLARIS THERAPEUTICS, INC.
- **STREET 2:** 640 LEE ROAD, SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aclaris Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001557746
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 460571712
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 640 LEE ROAD
- **STREET 2:** SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 484-324-7933

**MAIL ADDRESS:**
- **STREET 1:** 640 LEE ROAD
- **STREET 2:** SUITE 200
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

## Ex-24

```

Ex. 24.1

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

	Know all by these presents, that the undersigned hereby constitutes and
appoints each of Brian F. Leaf, Mark Ballantyne, Andrew Durand and Robin Lee of
Cooley LLP, and Douglas Manion of Aclaris Therapeutics, Inc. (the "Company"),
the undersigneds true and lawful attorneys-in-fact and agents to:

	(1)	Prepare, execute in the undersigneds name and on the undersigneds behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
Uniform Application for Access Codes to File on EDGAR, including amendments
thereto, and any other documents necessary or appropriate to obtain codes and
passwords enabling the undersigned to make electronic filings with the SEC of
reports required by Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or any rule or regulation thereunder;

	(2)	Prepare, execute in the undersigneds name and on the undersigneds behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Exchange Act and the rules thereunder in the undersigneds capacity as an
officer, director or beneficial owner of more than 10% of a registered class of
securities of the Company;

	(3)	Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and

	(4)	Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-facts discretion.

	The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in facts substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigneds
responsibilities to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigneds holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact is no longer employed
by the Company or Cooley LLP, as applicable.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Date: 	November 30, 2022

By:	/s/ Kevin Balthaser
	Kevin Balthaser

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Balthaser Kevin<br><sub>(Last) (First) (Middle)</sub><br>C/O ACLARIS THERAPEUTICS, INC.<br>640 LEE ROAD, SUITE 200<br><sub>(Street)</sub><br>WAYNE, PA 19087<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Aclaris Therapeutics, Inc. [ ACRS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Financial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 700 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | <sup>(1)</sup> | 2027-07-04 | Common Stock | 11200 | $27.54 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(1)</sup> | 2028-01-31 | Common Stock | 2100 | $22.09 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(2)</sup> | 2031-02-28 | Common Stock | 15500 | $24.06 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(3)</sup> | 2032-02-29 | Common Stock | 33400 | $14.94 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1475 | <sup>(5)</sup> | D |  |
| Restricted Stock Units | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 3000 | <sup>(5)</sup> | D |  |
| Restricted Stock Units | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 2000 | <sup>(5)</sup> | D |  |
| Restricted Stock Units | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 3300 | <sup>(5)</sup> | D |  |
| Restricted Stock Units | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 9500 | <sup>(5)</sup> | D |  |

---

### Footnotes:

(1) The shares underlying this option are fully vested. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.

(2) The option vests over a period of four years. 25% of the shares are currently vested with the remaining 75% vesting annually on March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.

(3) The option vests over a period of four years. 25% of the shares will vest on March 1, 2023, with the remaining 75% vesting annually thereafter on March 1, 2024, March 1, 2025 and March 1, 2026, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.

(4) The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

(5) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

(6) The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

(7) The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

(8) The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

(9) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.

**Remarks:**
Exhibit 24.1 - Power of Attorney

**Signature:** /s/ Mark Ballantyne, as Attorney-in-Fact  
**Date:** 2023-01-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**